What Is Ipamorelin?

What ipamorelin is

Ipamorelin is a synthetic pentapeptide — a short chain of just five amino acids. It belongs to a family of compounds called growth hormone secretagogues: molecules that don’t supply growth hormone directly but instead tell your body to make and release more of its own.

That distinction matters more than almost anything else on this page. Injecting ipamorelin is not the same as injecting growth hormone or testosterone. Ipamorelin is a signal. It travels to the pituitary gland at the base of your brain, knocks on a specific receptor, and the pituitary responds by releasing a pulse of the growth hormone it already produces. When the signal fades, the pulse fades. Your body’s own feedback systems stay in the loop.

Ipamorelin was first described in 1998 by a research group then connected to Novo Nordisk, who were searching for a cleaner way to stimulate growth hormone for conditions involving deficiency or muscle-wasting states such as post-surgical recovery. The compound that emerged was notable enough that the original paper called it “the first selective growth hormone secretagogue” — a label that has followed it ever since.

Note: Throughout this guide, “growth hormone” refers to your body’s own pituitary-derived hormone. Ipamorelin is a tool for prompting its release, not a synthetic version of it.

How it works

To understand ipamorelin you need one piece of background. Your stomach makes a hormone called ghrelin — most people know it as the “hunger hormone,” but ghrelin also happens to be one of the body’s natural triggers for growth hormone release. It does this by binding a receptor in the pituitary and hypothalamus called the growth hormone secretagogue receptor (GHS-R1a), sometimes just called the ghrelin receptor.

Ipamorelin is a ghrelin-receptor agonist. It mimics the shape ghrelin uses to fit that receptor, so when it reaches the pituitary it activates the same pathway and triggers a growth hormone pulse. In the language of the original research, it stimulates growth hormone release “via a GHRP-like receptor” — the same machinery used by an older family of peptides called the growth hormone-releasing peptides (GHRPs).

One feature that gets emphasized a lot online is that ipamorelin tends to preserve the natural pulsatile rhythm of growth hormone rather than forcing a flat, continuous elevation. Healthy growth hormone secretion comes in bursts, especially overnight, and the pulsatile pattern is part of how the signal stays biologically sensible. A secretagogue that works with that rhythm is, in theory, gentler on the system than one that overrides it — though “in theory” is doing real work in that sentence, as the next section explains.

What makes ipamorelin distinctive: selectivity

If ipamorelin works through the same receptor as the older GHRPs, why does anyone bother with it? The answer is selectivity, and it’s the single most important thing to understand about this molecule.

Earlier secretagogues like GHRP-6 and GHRP-2 do raise growth hormone — but they also pull up other hormones along for the ride. GHRP-6 is notorious for spiking appetite. Both can elevate cortisol (the stress hormone), prolactin, and ACTH. Those side effects aren’t trivial: chronically elevated cortisol works against many of the very goals people pursue growth hormone for.

In the foundational animal studies, ipamorelin released growth hormone with potency comparable to GHRP-6, but — strikingly — it did not meaningfully raise ACTH or cortisol, even at doses many times higher than the amount needed to release growth hormone. It also didn’t move prolactin, FSH, LH, or TSH. That clean profile is exactly why it earned the “first selective” title and why it became the secretagogue of choice in wellness circles.

A quick way to place ipamorelin among its neighbors:

• Versus GHRP-6 / GHRP-2: same general mechanism (ghrelin receptor), but cleaner — far less effect on cortisol, prolactin, and appetite.
• Versus CJC-1295, sermorelin, tesamorelin: a different mechanism entirely. Those are GHRH analogs — they work on the GHRH receptor, the other lever for growth hormone release. Ipamorelin works on the ghrelin receptor. Because the two levers complement each other, ipamorelin and a GHRH analog are frequently discussed as a pair. The head-to-head details live on our CJC-1295 vs ipamorelin page and in What is CJC-1295?.

What the research actually shows

Here is where an honest explainer has to slow down, because the gap between ipamorelin’s reputation and its evidence base is wide.

The mechanism is real and well characterized. The selectivity has been demonstrated, including in human pharmacokinetic work. What is largely missing is human outcome data — studies showing that ipamorelin actually improves the things people take it for.

Concretely, the human evidence amounts to a small number of pharmacokinetic and pharmacodynamic studies plus a Phase II clinical program that was discontinued. That early clinical work looked at settings like recovery of gut function after surgery — not muscle gain, fat loss, anti-aging, or sleep, which are the reasons ipamorelin is popular today. The bulk of the supporting research is in rodents, not people.

So the careful framing is this: ipamorelin reliably raises growth hormone in humans (that part is documented), but there is no robust human trial evidence that this translates into improved body composition, better sleep, faster injury recovery, or slowed aging. Those are plausible downstream hopes, not demonstrated outcomes. Higher growth hormone is a biomarker, not a guaranteed result you can see in the mirror — a distinction worth keeping in mind whenever you read marketing or anecdotes. We unpack each claimed benefit against its actual evidence tier on Ipamorelin benefits & uses.

The fact that a major Phase II program was discontinued is itself informative. Promising mechanisms regularly fail to clear the bar of showing meaningful, reproducible clinical benefit, and ipamorelin never crossed the finish line into an approved indication.

Its US legal status in 2026

This is the part where a lot of online information — including some that’s only a few months old — is simply out of date or wrong. Here is the accurate picture as of mid-2026.

Ipamorelin has never been FDA-approved for any use in the United States. That has not changed and is not changing in the near term. “Approved” and “available to compound” are different categories, and conflating them is the most common error in peptide coverage.

On the compounding question, the timeline is genuinely in motion:

• In September 2023, the FDA placed a group of peptide bulk substances — ipamorelin among them — into Category 2 of its interim 503A list, the category for substances flagged with potential safety concerns. In practice this meant licensed compounding pharmacies generally stopped preparing it.
• The nomination for ipamorelin (and several others) was later withdrawn, and in early 2026 a broader regulatory shift began. The companies’ withdrawals meant these peptides came off Category 2 effective April 23, 2026.
• The FDA’s Pharmacy Compounding Advisory Committee (PCAC) is scheduled to review whether to formally clear any of these peptides for compounding at its July 23–24, 2026 meeting.
• Formal rulemaking is still pending. Coming off Category 2 is not the same as being placed on the approved Category 1 list. Until the FDA publishes a final determination, the pathway for pharmacy-grade ipamorelin is unsettled rather than clearly open.

You may see confident claims that ipamorelin was “reclassified to Category 1 in February 2026.” That is not accurate. A February 2026 announcement signaled intent and direction, but the administrative process — the Category 2 removal, the PCAC review, and any final rule — runs on its own timeline, and as of this writing it is incomplete. Treat anyone selling certainty about the outcome with caution. Regulatory status is current as of the date at the top of this page and may change; our 2026 FDA peptide reclassification explainer tracks the moving parts, and Are peptides legal in the US? covers the wider legal frame.

How people access it — and the safety catch

Because compounding access has been restricted, most people pursuing ipamorelin in 2026 have been getting it from research-chemical suppliers that sell it labeled “for research use only,” not from licensed pharmacies. This is the central safety problem, and it deserves to be stated plainly.

Product bought this way is of unknown concentration and purity. A vial may contain more, less, or different material than the label claims; it isn’t made under pharmacy quality controls; and there’s no clinician monitoring whoever uses it. Peptides in this category can also carry an immunogenicity risk — the possibility of provoking an immune response — which is one of the safety considerations behind the regulatory caution in the first place.

The legitimate route, if and when compounding access is settled, runs through a licensed provider who evaluates you and, where appropriate, issues a prescription that a compounding pharmacy fills — with real product and real oversight. That is a fundamentally different thing from ordering an unverified vial online. We walk through the legal access routes, without sourcing instructions, on How to get ipamorelin in the US, and the cost realities on Ipamorelin cost in the US.

This site is educational. It does not sell, supply, or prescribe ipamorelin, and nothing here is a recommendation to use it. The honest bottom line is the one in the key takeaway: ipamorelin is a real, well-characterized molecule with a genuinely interesting selectivity profile — and a human evidence base, and a regulatory status, that are both thinner and more unsettled than its online popularity suggests.

Frequently asked questions

The questions people most often ask about ipamorelin are answered in the FAQ section accompanying this page, covering what it is, how it differs from CJC-1295 and other growth hormone peptides, its approval status, and where its 2026 US legal standing actually sits.